Efficacy and safety of topical methotrexate gel 1% in combination with microneedling vs. cryotherapy for the treatment of cutaneous warts: a prospective randomized controlled trial
Clinical and Experimental Dermatology · 2025
DOI: 10.1093/ced/llaf102 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Eman Riad Mohamed Hofny und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Faculty of Medicine, Assiut University, Egypt. Hauptthemen laut MEDLINE: Warts, Methotrexate, Cryotherapy, Dermatologic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Background
Cutaneous warts continue to represent a therapeutic challenge because of treatment resistance and the inconvenience of most modalities of treatment. Topical methotrexate (MTX) with improved delivery methods may be a viable tool for certain localized dermatological conditions. Regarding cutaneous warts, MTX, either topical or intralesional, is one of the promising lines of treatment.
Objectives
To investigate the efficacy and safety of topical MTX hydrogel 1% combined with microneedling in the treatment of cutaneous warts compared with traditional cryotherapy.
Methods
Sixty-eight patients with common or plantar warts were enrolled in this study. Patients were divided randomly into two groups: group A, which included 34 patients who received topical MTX hydrogel 1% combined with microneedling, and group B, which included 34 patients who received cryotherapy. All patients were followed up for 3 months after finishing treatment to detect any recurrence.
Results
Regarding size after treatment, the complete resolution of warts was higher in group B (65%, 22/34) than in group A (53%, 18/34). The difference between both groups in clinical response did not reach statistical significance. There was no statistically significant difference between groups A and B regarding pain and erythema (P = 0.28 and P = 0.51, respectively). The rates of blistering and hypopigmentation were significantly higher in group B than in group A (P < 0.001 and P < 0.05, respectively). During the 3-month follow-up period, no recurrence was found in either group.
Conclusions
Topical MTX hydrogel 1% combined with microneedling is an effective and safe therapeutic option in the treatment of common and plantar warts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Faculty of Medicine, Assiut University, Egypt.
- Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, Egypt.
- Institute of Drug Development and Innovation Research, Assiut University, Assiut, Egypt.
- Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Badr University in Assiut, Naser City, Assiut, Egypt.
ORCID-Profile: Eman Fathy, Heba Hassan
Zitieren
APA
Hofny, E. R. M., Alhakami, K. F., Abouelmagd, S. A., Hassan, S. A., Fathy, E., & Hassan, H. (2025). Efficacy and safety of topical methotrexate gel 1% in combination with microneedling vs. cryotherapy for the treatment of cutaneous warts: a prospective randomized controlled trial. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llaf102
Vancouver
Hofny ERM, Alhakami KF, Abouelmagd SA, Hassan SA, Fathy E, Hassan H. Efficacy and safety of topical methotrexate gel 1% in combination with microneedling vs. cryotherapy for the treatment of cutaneous warts: a prospective randomized controlled trial. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llaf102
BibTeX
@article{Hofny2025,
author = {Hofny, Eman Riad Mohamed and Alhakami, Khulood Fadhl and Abouelmagd, Sara A and Hassan, Sara A and Fathy, Eman and Hassan, Heba},
title = {Efficacy and safety of topical methotrexate gel 1% in combination with microneedling vs. cryotherapy for the treatment of cutaneous warts: a prospective randomized controlled trial},
journal = {Clinical and Experimental Dermatology},
year = {2025},
doi = {10.1093/ced/llaf102}
}
EUVIMED